US FDA Grants Approval to Novavax’s Protein-Based COVID-19 Vaccine, Nuvaxovid
The U.S. Food and Drug Administration (FDA) has approved Nuvaxovid, a COVID-19 vaccine developed by Novavax that uses a protein-based approach. Unlike mRNA or viral vector vaccines, protein-based vaccines are a type of subunit vaccine that includes only specific components of a virus—in this case, purified protein fragments selected for their ability to trigger an immune response.
These proteins are non-infectious and cannot replicate or cause illness. To enhance their effectiveness, they are combined with an adjuvant—an ingredient that boosts the body's immune reaction to the vaccine. Other subunit vaccines, such as polysaccharide and conjugate vaccines, use a similar strategy by presenting parts of pathogens to train the immune system without introducing the whole virus.
Protein-based vaccines like Nuvaxovid offer a traditional and well-understood method of immunization, potentially appealing to individuals seeking alternatives to newer vaccine technologies.
We have created our curriculum to suit the specific needs & capabilities of each student, ensuring that it is
the perfect fit for their unique requirements.
Rohini : D-11/156 Sector 8 Rohini LandMark: Opp-pillar No - 389 Rohini East Metro Station
Delhi-85
